While surgical resection remains the mainstay of treatment for localized melanoma, modern therapeutics with demonstrated efficacy in the metastatic setting, including immune checkpoint inhibitors and targeted therapy (BRAF and MEK inhibitors), have quickly made their way to the adjuvant setting for high-risk melanoma. Here, MAP2K7 is linked to melanoma.